We are committed to the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases

Landos Biopharma is a clinical-stage biotechnology company developing oral therapeutics to treat autoimmune diseases. BT-11, Landos’ lead asset, is currently being studied in a Phase 2 trial in ulcerative colitis (UC), with plans to initiate an additional Phase 2 trial in Crohn’s disease (CD). BT-11 is a small molecule that targets novel pathways within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient side effect profile.

View More